Novartis Ag

Novartis Pharmaceuticals Corporation

Novartis Pharma Gmbh

Piotr Henryk Karpinski

Paul Allen Sutton

Mahavir Prashad

Raeann Wu

Yugang Liu

Liladhar Murlidhar Waykole

Lili Feng

Stéphanie Monnier

Paul William Manley

Wen-Chung Shieh

Thomas J Blacklock

Michael John Girgis

Bin Hu

Sven Erik Godtfredsen

Jörg Brozio

Mark G Bock

Dario Braga

Yves Auberson

Thomas Josef Troxler

Edwin Bernard Villhauer

Stephanie Kay Dodd

Stefano Luca Giaffreda

Xiaoyang Wang

Wolfgang Marterer

Bertrand Sutter

Denis Har

Jean-Claude Bianchi

Xuechun Zhang

Marilyn De La Cruz

Eckart Buerger

Doris Stingelin

Massimo Pignone

Marco Curzi

James Anthony Vivelo

Augustus O Okhamafe

Tie-Lin Wang

Ahmad Hashash

Eric M Loeser

Dimitris Papoutsakis

Kangwen L Lin

Rampurna Gullapalli

Eduardo Sy

Haiyang Jiang

Joerg Brozio

Prasad Koteswara Kapa

Murat Acemoglu

Frank Stowasser

Lech Andrzej Ciszewski

Hui Liu

Baoqing Gong

Joel Slade

John Vincent Calienni

Joginder S Bajwa

Caspar Vogel

Maria Caterina Testa

Pascal Michel

Xinglong Jiang

Tielin Wang

Hayang Jiang

Lilli Feng

Elias Ndzie

Ricardo Schneeberger

Ricardo Sschneeberger

Christian Riegert

Rasmus Mose

Mark Gary Bock

Thomas Blacklock

Dietmar Flubacher

Michael Mutz

Jorg Brozio

An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.

Amorphous solid form of compounds containing S&#x2014;N-valeryl-N- {[2'-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations

An amorphous solid form of a compound comprising the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This compound is useful for the treatment of hypertension and/or heart failure.

Amorphous solid form of compounds containing S&#x2014;N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Carbamate/urea derivatives

A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.

Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations

Salts of aza-bicyclic di-aryl ethers and pharmaceuticals thereof

The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease.

Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine

The invention relates to new crystalline forms of processes for manufacturing a compound of formula 5, or a stereoisomer, tautomer or a salt thereof, wherein the substituents are as defined in the specification. The invention further relates to new manufacturing processes for specific solid forms of Compound A and its salts, to such solid forms and to use of said solid forms for the therapeutic treatment of warm-blooded animals.

Manufacturing process for pyrimidine derivatives

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S&#x2014;N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3&#x2032;-methyl-2&#x2032;-(pentanoyl{2&#x2033;-(tetrazol-5-ylate)biphenyl-4&#x2032;-ylmethyl}amino)butyrate] hemipentahydrate.

Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations

The invention relates to a new crystalline form of the acetate salt of which may be used, for example, for prevention or treatment of transplant rejection.

[object Object]

This invention relates to a hydrochloride, malate, oxalate and tartrate salt forms of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of each of these salts, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

Salts

Growing community of inventors

Lincoln Park, NJ, United States of America

Piotr Henryk Karpinski